State of art in antibody engineering for better therapeutic antibodies

With the advent of advanced technology, we can now reach the targets that previously known as "undruggable" due to the availability of high diversity antibodies. However, finding the right candidates among the high diversity antibodies can be time-consuming, and researchers would have experienced challenges such as missing out good binders, poor antibody library coverage, throughout the discovery and development workflow.

Several attempts have been made to address these challenges. Recently, the development of synthetic biology provides the breakthrough that allow the researchers to precisely define and control the synthesis of high-diversity domain libraries. The optimization process usually requires several rounds of the mutant library construction and screening in order to isolate the top ideal candidate.

In this webinar, you will learn

How to rapidly identify and validate a diverse repertoire of high-affinity antibodies

How to further improve the binding affinity of the antibody while reducing the screening burden during the optimization process

In this webinar, you will learn

Webinar Details

  • Date: 27th May 2021
  • Time: 10:00 AM SGT
  • Speaker:
 Dr. Edward Wong Dr. Edward Wong

Field Application Scientist, GenScript

Dr. Edward Wong is a field application scientist in GenScript. He completed his Ph.D. degree from University of Adelaide. He worked as a Post Doctoral fellow at National Cancer Centre Singapore for 3 years and he had successfully reported the predictive factors for genetic screening of BRCA1 and BRCA2. He also reported the importance of genetic testing for 25 breast cancer-predisposition genes using NGS technology. Both of his works were reported in PlosOne and npj Genomic Medicine.

Related Products and Services

Speaker-related Webinars

feedback

Do you like the current new website?

Hate

Dislike

Neutral

Like

Love

*